• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    Director Welgus Howard G. was granted 7,609 shares, increasing direct ownership by 7% to 119,553 units (SEC Form 4)

    6/16/25 8:17:58 PM ET
    $ARQT
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $ARQT alert in real time by email
    SEC FORM 4 SEC Form 4
    FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

    Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
    or Section 30(h) of the Investment Company Act of 1940
    OMB APPROVAL
    OMB Number: 3235-0287
    Estimated average burden
    hours per response: 0.5
      
    Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
      
    Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
    1. Name and Address of Reporting Person*
    Welgus Howard G.

    (Last) (First) (Middle)
    C/O ARCUTIS BIOTHERAPEUTICS, INC.
    3027 TOWNSGATE ROAD, SUITE 300

    (Street)
    WESTLAKE VILLAGE CA 91361

    (City) (State) (Zip)
    2. Issuer Name and Ticker or Trading Symbol
    Arcutis Biotherapeutics, Inc. [ ARQT ]
    5. Relationship of Reporting Person(s) to Issuer
    (Check all applicable)
    X Director 10% Owner
    Officer (give title below) Other (specify below)
    3. Date of Earliest Transaction (Month/Day/Year)
    06/12/2025
    4. If Amendment, Date of Original Filed (Month/Day/Year)
    6. Individual or Joint/Group Filing (Check Applicable Line)
    X Form filed by One Reporting Person
    Form filed by More than One Reporting Person
    Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
    1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
    Code V Amount (A) or (D) Price
    Common Stock 06/12/2025 A 7,609(1) A $0 119,553 D
    Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
    (e.g., puts, calls, warrants, options, convertible securities)
    1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
    Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
    Stock Option (right to buy) $13.5 06/12/2025 A 20,568 (2) 06/12/2035 Common Stock 20,568 $0 20,568 D
    Explanation of Responses:
    1. Represents restricted stock units ("RSUs") granted in connection with the Reporting Person's service as a non-employee director as of the Company's 2025 annual meeting of stockholders. The Reporting Person is entitled to receive one (1) share of common stock for each one (1) RSU upon the vesting thereof, which shall occur on the earlier of the first anniversary of the grant date, June 12, 2025, or immediately before the next annual meeting of stockholders, subject to the continued service through the vesting date.
    2. The underlying shares subject to the option vest and become exercisable as to 100% on the earlier of the first anniversary of the grant date, June 12, 2025, or immediately before the next annual meeting of stockholders, subject to the continued service through the vesting date.
    Remarks:
    Exhibit List: Exhibit 24.1 - Power of Attorney
    /s/ Latha Vairavan, as Attorney-in-Fact for Howard G. Welgus 06/16/2025
    ** Signature of Reporting Person Date
    Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
    * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
    ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
    Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
    Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
    Get the next $ARQT alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $ARQT

    DatePrice TargetRatingAnalyst
    12/30/2024$19.00Buy
    H.C. Wainwright
    8/28/2024$15.00Buy
    Jefferies
    1/3/2024$4.00 → $8.00Neutral → Buy
    Mizuho
    10/26/2023$57.00 → $4.00Buy → Neutral
    Mizuho
    10/13/2023$32.00 → $6.00Buy → Neutral
    Goldman
    9/7/2022$46.00Buy
    Needham
    3/17/2022$45.00Buy
    Goldman
    3/2/2022$35.00 → $37.00Overweight
    Morgan Stanley
    More analyst ratings

    $ARQT
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

      WESTLAKE VILLAGE, Calif., July 03, 2025 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT), a commercial-stage biopharmaceutical company focused on developing meaningful innovations in immuno-dermatology, today reported the grant of an aggregate of 14,000 restricted stock units of Arcutis' common stock to two newly hired employees. These awards were approved by the Compensation Committee of Arcutis' Board of Directors and granted under the Arcutis Biotherapeutics, Inc. 2022 Inducement Plan, with a grant date of July 1, 2025, as an inducement material to the new employees entering into employment with Arcutis, in accordance with Nasdaq Listing Rule 5635(c)(4). The restricted

      7/3/25 4:00:00 PM ET
      $ARQT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Arcutis' ZORYVE® (roflumilast) Cream 0.15% Receives Strong Recommendation in American Academy of Dermatology Updated Guidelines for Adult Atopic Dermatitis

      The American Academy of Dermatology (AAD) provided evidence-based recommendation for the use of ZORYVE® (roflumilast) cream 0.15% in adults with mild to moderate atopic dermatitis (AD)Recommendation reflects ZORYVE's proven efficacy, safety, and tolerability as a next-generation, steroid-free, topical phosphodiesterase-4 (PDE4) inhibitorAmong newly evaluated branded topical therapies, ZORYVE is the only treatment with a strong recommendation for adults with mild to moderate atopic dermatitis in AAD's focused guideline updateZORYVE is the first FDA-approved branded topical PDE4 inhibitor indicated for AD, plaque psoriasis, and seborrheic dermatitisAD impacts over 16 million adults in the Unit

      6/26/25 8:00:00 AM ET
      $ARQT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Arcutis Enrolls First Child in INTEGUMENT-INFANT Evaluating ZORYVE® (roflumilast) Cream 0.05% in Infants with Atopic Dermatitis

      Four-week Phase 2 study to evaluate investigational, once-daily ZORYVE .05% in infants as young as 3 months to less than 2 years with atopic dermatitisAtopic dermatitis impacts 9.6 million children in the United States; up to 60% of children with atopic dermatitis develop symptoms within their first year WESTLAKE VILLAGE, Calif., June 10, 2025 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT), a commercial-stage biopharmaceutical company focused on developing meaningful innovations in immuno-dermatology, today announced that the first child has been enrolled in a Phase 2 open-label study, INTEGUMENT-INFANT, evaluating the safety and tolerability of investigational ZORYVE (ro

      6/10/25 8:00:00 AM ET
      $ARQT
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ARQT
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • H.C. Wainwright initiated coverage on Arcutis Biotherapeutics with a new price target

      H.C. Wainwright initiated coverage of Arcutis Biotherapeutics with a rating of Buy and set a new price target of $19.00

      12/30/24 7:23:09 AM ET
      $ARQT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Jefferies initiated coverage on Arcutis Biotherapeutics with a new price target

      Jefferies initiated coverage of Arcutis Biotherapeutics with a rating of Buy and set a new price target of $15.00

      8/28/24 7:20:44 AM ET
      $ARQT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Arcutis Biotherapeutics upgraded by Mizuho with a new price target

      Mizuho upgraded Arcutis Biotherapeutics from Neutral to Buy and set a new price target of $8.00 from $4.00 previously

      1/3/24 7:32:19 AM ET
      $ARQT
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ARQT
    SEC Filings

    See more
    • Arcutis Biotherapeutics Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders, Other Events, Financial Statements and Exhibits

      8-K - Arcutis Biotherapeutics, Inc. (0001787306) (Filer)

      6/17/25 4:52:21 PM ET
      $ARQT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SCHEDULE 13G/A filed by Arcutis Biotherapeutics Inc.

      SCHEDULE 13G/A - Arcutis Biotherapeutics, Inc. (0001787306) (Subject)

      5/15/25 5:41:18 PM ET
      $ARQT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SCHEDULE 13G/A filed by Arcutis Biotherapeutics Inc.

      SCHEDULE 13G/A - Arcutis Biotherapeutics, Inc. (0001787306) (Subject)

      5/8/25 5:59:00 PM ET
      $ARQT
      Biotechnology: Pharmaceutical Preparations
      Health Care